FDA Okays Weekly Option in Achondroplasia - Poll - MDSpire

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

  • By

  • Kathryn Wighton

  • March 2, 2026

  • 2 min

Share

Original Source(s)

FDA Okays Weekly Option in Achondroplasia

  • by Kathryn Wighton

  • March 2, 2026

Related Content

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.